Description
Introduction:
Interleukin-10, human cytokine synthesis inhibitory factor (CSIF), is group of related proteins made by leukocytes and other body cells. It is an anti-inflammatory cytokine. IL-10 plays a key role in differentiation and function of a newly appreciated type of T cell, the T regulatory cell, which prominently control immune responses and tolerance. Interleukin-10 has 20 molecules in their pipeline developed by companies and universities.
Interleukin 10 Pipeline Product Analysis includes products such as AM-0010, ANV-103, BT-063, DEKAVIL/F8 IL10, EG-12, LEO-32731, MK-1966, PD-2244, XT-101, XT-150, Gene Therapy to Activate Interleukin 10 for Atherosclerosis, Gene Therapy to Activate Interleukin-10 for ALS, XT-150, Gene Therapy to Activate Interleukin 10 for Atherosclerosis, Gene Therapy to Activate Interleukin-10 for ALS, Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 Diabetes, Biologic to Target Gluten and IL-10 for Celiac Disease, Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation, Synthetic Peptides to Inhibit IL-10 and IFN Gamma for Cancer, and Viral Infections and Inflammatory Diseases.
Study objectives of Interleukin 10 Pipeline Product Analysis market:
• To provide a snapshot of the global therapeutic landscape for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10).
• To review Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• To provide descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
• To determine the key players involved in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics and enlists all their major and minor projects.
• To assess Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
Target Audience:
• Companies with Interleukin-10 products
• Government Research Laboratories
• Academic Universities/Institutes
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Medical Research Laboratories
Key Findings:
• The Interleukin-10 (IL-10) – Pipeline Review involves featured 18 products in pipeline.
• 9 products are in preclinical trials, 4 in phase II, 2 in phase I and 2 studies were discontinued due to tolerance issues.
Key Players:
• The leading market players in the global Interleukin 10 Pipeline Product Analysis include Pfizer Inc., Merck & Co., Inc, Biotest AG, BioMAS Ltd, EnGene Inc., Leo Pharma, Anvil Biosciences, Intrexon Corporation, P2D Biosciences, Xalud Therapeutics INC and others.
1 Report Prologue
2 Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Methodology
2.2.2 Assumptions
2.3 Limitations
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Rising Launch of New Concepts by Key Manufacturers
4.2.2 Larger Patient Base
4.3 Restraints
4.3.1 Stringent Regulatory Guidelines for the Use of the Drugs
4.4 Mega Trends
4.4.1 Development of New Technology for the Treatment of Disease
4.4.2 Macroeconomic Indicators
5 Market Factor Analysis
5.1 Value Chain Analysis
6 Stages of Clinical Trials
6.1 Preclinical Trial
6.2 Phase I Clinical Trial
6.3 Phase II Clinical Trial
6.4 Phase III Clinical Trial
6.5 Phase IV Clinical Trial
7 Interleukin 10 Pipeline Product Analysis, By Product
7.1 AM-0010
7.1.1 Product Description
7.1.2 Mechanism of Action
7.1.3 Clinical Trial Progress
7.2 ANV-103
7.2.1 Product Description
7.2.2 Mechanism of Action
7.2.3 Clinical Trial Progress
7.3 AS-101
7.3.1 Product Description
7.3.2 Mechanism of Action
7.3.3 Clinical Trial Progress
7.4 BT-063
7.4.1 Product Description
7.4.2 Mechanism of Action
7.4.3 Clinical Trial Progress
7.5 DEKAVIL/F8 IL10
7.5.1 Product Description
7.5.2 Mechanism of Action
7.5.3 Clinical Trial Progress
7.6 EG-12
7.6.1 Product Description
7.6.2 Mechanism of Action
7.6.3 Clinical Trial Progress
7.7 LEO-32731
7.7.1 Product Description
7.7.2 Mechanism of Action
7.7.3 Clinical Trial Progress
7.8 MK-1966
7.8.1 Product Description
7.8.2 Mechanism of Action
7.8.3 Clinical Trial Progress
7.9 PD-2244
7.9.1 Product Description
7.9.2 Mechanism of Action
7.9.3 Clinical Trial Progress
7.10 XT-101
7.10.1 Product Description
7.10.2 Mechanism of Action
7.10.3 Clinical Trial Progress
7.11 XT-150
7.11.1 Product Description
7.11.2 Mechanism of Action
7.11.3 Clinical Trial Progress
7.12 Gene Therapy to Activate Interleukin 10 for Atherosclerosis
7.12.1 Product Description
7.12.2 Clinical Trial Progress
7.13 Gene Therapy to Activate Interleukin-10 for ALS
7.13.1 Clinical Trial Progress
7.14 Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 Diabetes
7.14.1 Clinical Trial Progress
7.15 Biologic to Target Gluten and IL-10 for Celiac Disease
7.15.1 Clinical Trial Progress
7.16 Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation
7.16.1 Clinical Trial Progress
7.17 Synthetic Peptides to Inhibit IL-10 and IFN Gamma for Cancer, Viral Infections and Inflammatory Diseases
7.17.1 Clinical Trial Progress
8 Competitive Landscape
8.1 Acquisitions & Partnership
8.1.1 Pfizer Acquire Anacor
8.1.2 Merck Aquire IOmet
8.1.3 Takeda and EnGene Establish Strategic Alliance
9 Company Profile
9.1 Pfizer Inc.
9.1.1 Overview
9.1.2 Product Overview
9.1.3 Financials
9.1.4 Key Developments
9.2 Merck & Co., Inc.
9.2.1 Overview
9.2.2 Product Overview
9.2.3 Financials
9.2.4 Key Developments
9.3 Biotest AG
9.3.1 Overview
9.3.2 Product Overview
9.3.3 Financials
9.3.4 Key Developments
9.4 BioMAS Ltd.
9.4.1 Overview
9.4.2 Product Overview
9.4.3 Financials
9.4.4 Key Developments
9.5 EnGene Inc.
9.5.1 Overview
9.5.2 Product Overview
9.5.3 Financials
9.5.4 Key Developments
9.6 Leo Pharma
9.6.1 Overview
9.6.2 Product Overview
9.6.3 Financials
9.6.3 Financials
9.6.4 Key Developments
9.7 Anvil Biosciences
9.7.1 Overview
9.7.2 Product Overview
9.7.3 Financials
9.7.4 Key Developments
9.8 Intrexon Corporation
9.8.1 Overview
9.8.2 Product Overview
9.8.3 Financials
9.8.4 Key Developments
9.9 P2D Biosciences
9.9.1 Overview
9.9.2 Product Overview
9.9.3 Financials
9.9.4 Key Developments
9.10 Xalud Therapeutics INC.
9.10.1 Overview
9.10.2 Product Overview
9.10.3 Financials
9.10.4 Key Developments
